Sensor and Software Use for Improved Glucose Control in MDI Managed Diabetes

Sensor and Software Use for Improved Glucose Control in MDI Managed Diabetes

To understand if Multiple Daily Injections (MDI) managed subjects can improve glycaemic control by;

1. regularly checking and understanding Continuous Glucose data & trend arrows at times other than the standard pre-meal bolus calculation test times and
2. review of their glucose profiles (inc. hypoglycaemic risks) with their Health Care Professional (HCP) and adjusting behaviours & therapy from interpretation of the Continuous Glucose profiles.

Inclusion Criteria:

• Age 18 years and over
• Type 1 diabetes on MDI with bolus injections for >6 months prior to study enrolment or Type 2 diabetes treated with 2 or more insulin injections daily.
• In the investigator's opinion, thought technically capable of using FreeStyle Navigator GM System device.
• HbA1c between 7.5 and 12.0% (58 to 108 mmol/mol) for previous test obtained within 6 months prior to point of enrolment

Exclusion Criteria:

• Concomitant disease or condition that may compromise patient safety, including unstable coronary heart disease, cystic fibrosis, serious psychiatric disorder, or any uncontrolled chronic medical condition
• Female subject is pregnant or planning to become pregnant within the planned study duration. Subjects who become pregnant during the study will be discontinued from the study.
• Currently using / has previously used a Continuous Glucose Monitoring System within the last 6 months.
• Currently using Continuous Subcutaneous Insulin Infusion (CSII)
• Currently using basal/long acting insulin only.
• Participating in another study of a glucose monitoring device / drug that could affect glucose measurements / management
• Known allergy to medical grade adhesives
• In the investigators opinion is unsuitable to participate due to any other cause/reason.